Acer Therapeutics (NASDAQ:ACER) issued its earnings results on Friday. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.10, MarketWatch Earnings reports.
NASDAQ ACER traded up $0.29 during mid-day trading on Friday, reaching $24.91. 7,116 shares of the stock were exchanged, compared to its average volume of 29,773. Acer Therapeutics has a 1-year low of $11.36 and a 1-year high of $34.10. The firm has a market cap of $242.20 million, a P/E ratio of -6.49 and a beta of 2.75.
Several research firms have recently commented on ACER. William Blair reiterated an “outperform” rating on shares of Acer Therapeutics in a research report on Tuesday, August 14th. BidaskClub lowered shares of Acer Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 4th. HC Wainwright set a $55.00 target price on shares of Acer Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 15th. Raymond James upgraded shares of Acer Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $31.00 to $46.00 in a research report on Friday, August 17th. Finally, Zacks Investment Research lowered shares of Acer Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $48.00.
ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/11/10/acer-therapeutics-acer-issues-quarterly-earnings-results.html.
Acer Therapeutics Company Profile
Acer Therapeutics Inc, a pharmaceutical company, develops therapies for the treatment of rare diseases with critical unmet medical needs. Its product candidates include Celiprolol for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001 for the treatment of urea cycle disorders and maple syrup urine disease.
Read More: What is a stock buyback?
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.